Dialysis drug may shield brain from 'Fog' and stroke risk

NCT ID NCT07234890

First seen Nov 19, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests a new medication called AV-001 in 60 adults who have been on dialysis for at least 3 months. The goal is to see if AV-001 can strengthen brain blood vessels and reduce inflammation, potentially preventing memory problems and thinking difficulties caused by dialysis. Participants will receive either a high dose, low dose, or placebo, and brain changes will be tracked using MRI and blood tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.